Our Purpose
The Clinical Proteomics Platform aims to exploit the latest technological developments in mass spectrometry and immunoassay for the discovery, validation and use of biomarkers in various human pathologies (proteins, RNA, DNA, metabolites).
Our Approach
Several technological approaches oriented towards the use of clinical samples and high throughput are available, including mass spectrometry (MRM and HRMS) and ultra-sensitive immunoassays (SIMOA and MSD).
Our Mission
Integrated in the Montpellier Proteome Cluster since its creation and IBiSA labeled, its mission is equally to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams. The PPC has been ISO 9001 certified since 2014.
Latest news :
IMSC 2026 in Lyon
The PPC is very proud of Dr Jérôme Vialaret and his brillant presentation. This year the IMSC was held in Lyon, where Jérôme had the oppportunity to present: Multiplex targeted mass spectrometry improves CSF-based biological stratification across neurodegenerative...
Kōichi Tanaka, Docteur Honoris Causa
The Montpellier School of Dentistry had the honor of welcoming Kōichi Tanaka, winner of the 2002 Nobel Prize in Chemistry, on the occasion of his appointment as an honorary doctorate recipient at the University of Montpellier. This distinction, supported by Prof....
CSF Society 2026
This year, the 5th meeting of the society for CSF analysis and clinical neurochemistry was held in Montpellier on the 4th and 5th of June 2026. This conferernce brings together students, PhD candidates, postdoctoral researchers, senior scientists, and clinicians...
The PPC in a nutshell :
Employees
Years of experience
Ongoing projects
Patents
Clinical Proteomics Platform
Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE